Malabsorption Syndrome Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, UK, Canada - Size and Forecast 2024-2028

Malabsorption Syndrome Market Size 2024-2028 

The malabsorption syndrome market size is forecast to increase by USD 843 million and is estimated to grow at a CAGR of 4.5% between 2023 and 2028. Gluten intolerance and lactose intolerance are common dietary restrictions that have gained significant attention in recent years. The consumption of gluten-containing foods, such as wheat, barley, and rye, can cause adverse health effects for those with gluten intolerance or celiac disease. Similarly, lactose intolerance affects the ability to digest lactose, a sugar found in milk and dairy products. Both conditions can lead to digestive discomfort, bloating, and other symptoms. The increasing prevalence of these conditions has led to a growing demand for alternative food options. Government initiatives and awareness programs have played a crucial role in promoting the availability and acceptance of gluten-free and lactose-free products. These efforts have resulted in a wider range of options for individuals with dietary restrictions, making it easier for them to maintain a healthy and balanced diet. In summary, the rising awareness of gluten intolerance and lactose intolerance, coupled with government initiatives and advancements in food technology, has led to an increase in the availability and acceptance of alternative food options for those with dietary restrictions.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

Malabsorption Syndrome Market: Overview and Growth Dynamics Malabsorption syndrome is a digestive disorder characterized by the inability to absorb essential nutrients such as lipids, vitamins, carbohydrates, and proteins from food. The condition can be caused by various factors including intestinal inflammation, celiac disease, cystic fibrosis, Crohn's disease, lactose intolerance, parasite illnesses, gallbladder, and liver disease. Unmet medical demands, healthcare spending, regulatory framework, adoption rate, financing, and reimbursement policies are key factors influencing the growth of the malabsorption syndrome market. The market for malabsorption syndrome is expected to witness significant growth due to the increasing prevalence of underlying conditions that cause malabsorption. For instance, celiac disease affects an estimated 1 in 100 people worldwide, while cystic fibrosis affects approximately 70,000 people globally. Moreover, antibiotic usage, physical distancing protocols, and lockdowns due to the COVID-19 pandemic have disrupted the pharmaceutical supply chain, leading to a shortage of essential medications for managing malabsorption syndrome. Pharmaceutical and biotech businesses are investing in vaccine research and development to address unmet medical needs in malabsorption syndrome. For instance, hydroxychloroquine, a drug used to treat malabsorption syndrome, has gained significant attention due to its potential role in managing COVID-19. However, the regulatory approval process and reimbursement policies for these treatments can impact market growth. In summary, the malabsorption syndrome market is expected to grow due to the increasing prevalence of underlying conditions, healthcare spending, and regulatory framework. Pharmaceutical and biotech businesses are investing in research and development to address unmet medical needs, while the disruption of the pharmaceutical supply chain and regulatory approval processes pose challenges to market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

Higher consumption of gluten-containing food is notably driving market growth. Malabsorption Syndrome, specifically Sprue Disease, is a digestive disorder characterized by the inability to absorb essential nutrients due to impaired digestion. Gluten, a protein found in wheat, barley, and rye, is a common cause of this syndrome.

Moreover, foods such as pizza, cake, soups, beer, bread, cookies, pasta, and burgers are among the widely consumed items containing gluten. The global consumption of these foods, particularly fast foods like pizza and burgers, is on the rise. For instance, in the US, approximately 30% of the population consumes pizza on a typical day. This trend is linked to various digestive disorders, including celiac disease or Sprue Disease. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

Increased prevalence of cystic fibrosis in Europe, North America, and South America is the key trend in the market. The global market for Malabsorption Syndrome is witnessing significant growth due to the increasing prevalence of digestive disorders, particularly cystic fibrosis, in regions such as Europe, North America, and South America.

Moreover, cystic fibrosis affects approximately one out of every 25,000 individuals in North America and one out of every 3,500 individuals in South America. Europe has the highest reported prevalence of the disease, while Asia has the lowest. This high prevalence has led to the development of new treatments, including antibiotics, surgery, and digestive enzymes, by leading industry players. Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenge

Shifting preferences towards dairy-free alternatives is the major challenge that affects the growth of the market. Malabsorption Syndrome, a group of digestive disorders, necessitates the utilization of various treatments, including antibiotics, surgery, and digestive enzymes. The market for these treatments is subject to stringent safety standards and regulatory oversight.

Moreover, clinical trials are essential to ensure the efficacy and safety of new products. Trained personnel are required to administer these treatments, adhering to safety regulations. The product pipeline analysis of Malabsorption Syndrome drugs includes several revenue pockets, with digestive enzymes being a significant area of focus. Hence, the above factors will impede the growth of the market during the forecast period.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc: The company offers malabsorption syndrome drugs namely Delzicol DR Capsules.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Aspen Pharmacare Holdings Ltd.
• Bausch Health Companies Inc.
• Baxter International Inc.
• Cosmo Pharmaceuticals NV
• Ferring BV
• Koninklijke DSM NV
• Lannett Co. Inc.
• Merck and Co. Inc.
• Novartis AG
• Organon and Co.
• Perrigo Co. Plc
• Pfizer Inc.
• ProThera Biologics Inc.
• Sanofi SA
• Tillotts Pharma AG
• Xspire Pharma LLC

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

By Disease Type 

The lactose intolerance segment is estimated to witness significant growth during the forecast period. The Market encompasses various digestive disorders, including celiac disease, cystic fibrosis, Crohn's disease, lactose intolerance, parasite illnesses, gallbladder, and liver diseases, among others. These conditions result in the inability to absorb essential nutrients such as lipids, vitamins, carbohydrates, and proteins from food.

Get a glance at the market share of various regions Download the PDF Sample

The lactose intolerance segment was the largest segment and valued at USD 1.24 billion in 2018. The unmet medical demands in this area have led to significant healthcare spending, particularly in middle-income countries. The regulatory framework plays a crucial role in the adoption rate of treatments and interventions for malabsorbption syndromes. Financing and reimbursement policies vary across regions, influencing the market dynamics. For instance, pharmaceutical and biotech businesses are investing in vaccine research and innovative interventions, such as hydroxychloroquine, to address malabsorption syndromes related to cancers and radiation therapy. Hence, such factors are fuelling the growth of this segment during the forecast period.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

Europe is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Malabsorption Syndrome, a condition characterized by the intestine's inability to absorb essential nutrients such as lipids, vitamins, carbohydrates, and proteins, presents significant unmet medical demands worldwide. The healthcare spending on digestive diseases, including malabsorption syndrome, is projected to increase due to the rising prevalence of underlying conditions like celiac disease, cystic fibrosis, Crohn's disease, lactose intolerance, parasite illnesses, gallbladder, and liver diseases, among others. Hence, such factors are driving the market in Europe during the forecast period.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments

• Disease Type Outlook
  • Lactose intolerance
  • Sprue
  • Cystic fibrosis
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

You may also interested in below market reports:

• Gastrointestinal Diseases Therapeutics Market Analysis North America, Asia, Europe, Rest of World (ROW) - US, Japan, China, Germany, France - Size and Forecast
• Infectious Enteritis Treatment Market by Route of Administration and Geography - Forecast and Analysis
• Oral Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, India, UK - Size and Forecast

Market Analyst Overview

Malabsorption syndrome is a digestive disorder that impedes the intake of essential nutrients such as lipids, vitamins, carbohydrates, and proteins. Unmet medical demands for effective treatments continue to drive healthcare spending in this area. The regulatory framework plays a crucial role in the adoption rate of new therapies. Financing and reimbursement policies are significant factors influencing the market growth. Conditions like celiac disease, cystic fibrosis, Crohn's disease, lactose intolerance, parasite illnesses, gallbladder, and liver disease contribute to the high prevalence of malabsorption syndrome. Antibiotic usage and intestinal inflammation are other contributing factors. The pharmaceutical and biotech businesses are focusing on innovative interventions, including vaccine research, to address these conditions. The lockdown and physical distancing protocols have impacted the pharmaceutical supply chain, affecting the availability of essential medications. Middle-income countries are expected to witness significant growth due to increasing healthcare costs and a regulatory environment that supports R&D initiatives. Hydroxychloroquine and biotechnology sectors are some of the vaccine candidates under investigation. The Celiac Disease Foundation and other organizations are advocating for financial support to accelerate research and development. Cancer patients undergoing radiation therapy also experience malabsorption syndrome, adding to the market demand.

Download PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies